KLK3 and neoplasm: Low- to intermediate risk patients were selected with T1 or T2 tumor stages, low pre-treatment PSA levels and low Gleason scores, with no lymph node or distant metastases at the time of enrolment, indicating a relatively homogeneous patient group with good prognostic criteria (Table 1).